Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DTIL Stock Forecast 2025-2026
$4.45
Current Price
$54.69M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DTIL Price Targets
+1,248.3%
To High Target of $60.00
+450.6%
To Median Target of $24.50
+192.1%
To Low Target of $13.00
DTIL Price Momentum
+2.5%
1 Week Change
-9.2%
1 Month Change
-56.1%
1 Year Change
+16.8%
Year-to-Date Change
-59.9%
From 52W High of $11.09
+23.3%
From 52W Low of $3.61
📊 TOP ANALYST CALLS
Did DTIL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Precision BioSciences is one of their latest high-conviction picks.
Latest DTIL Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, DTIL has a bullish consensus with a median price target of $24.50 (ranging from $13.00 to $60.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $4.45, the median forecast implies a 450.6% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,248.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DTIL Analyst Ratings
4
Buy
0
Hold
0
Sell
DTIL Price Target Range
Low
$13.00
Average
$24.50
High
$60.00
Current: $4.45
Latest DTIL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DTIL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jan 10, 2025 | BMO Capital | Kostas Biliouris | Outperform | Upgrade | $34.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Apr 30, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Initiates | $19.00 |
| Apr 17, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $60.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
| Sep 19, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $3.00 |
| Aug 7, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $0.00 |
| Jul 28, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 28, 2023 | BTIG | Thomas Shrader | Buy | Maintains | $2.00 |
| Jun 1, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
| Mar 15, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
Precision Biosciences Inc. (DTIL) Competitors
The following stocks are similar to Precision BioSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Precision Biosciences Inc. (DTIL) Financial Data
Precision Biosciences Inc. has a market capitalization of $54.69M with a P/E ratio of 4.4x. The company generates $51.14M in trailing twelve-month revenue with a -43.0% profit margin.
Revenue growth is -99.8% quarter-over-quarter, while maintaining an operating margin of -76,248.3% and return on equity of -50.8%.
Valuation Metrics
Market Cap
$54.69M
Enterprise Value
$-904,417
P/E Ratio
4.4x
PEG Ratio
-0.7x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
-99.8%
Gross Margin
N/A
Operating Margin
-76,248.3%
Net Margin
-43.0%
EPS Growth
-99.8%
Financial Health
Cash/Price Ratio
+156.5%
Current Ratio
6.6x
Debt/Equity
60.3x
ROE
-50.8%
ROA
-17.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Precision Biosciences Inc. (DTIL) Business Model
About Precision Biosciences Inc.
What They Do
Develops gene editing technologies for health.
Business Model
The company leverages its proprietary ARCUS genome editing platform to create therapeutic solutions for genetically-defined diseases, primarily generating revenue through the development of allogeneic CAR T cell therapies aimed at treating cancer. By focusing on precision editing and targeting specific diseases, it positions itself within the lucrative biopharmaceutical market.
Additional Information
Founded in 2006 and based in Durham, North Carolina, Precision Biosciences is dedicated to advancing personalized medicine and precision therapeutics, playing a significant role in addressing unmet medical needs through innovative genetic and cellular solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
107
CEO
Mr. Michael Amoroso
Country
United States
IPO Year
2015
Website
precisionbiosciences.comPrecision Biosciences Inc. (DTIL) Latest News & Analysis
Latest News
Quick Summary
Precision BioSciences' PBGENE-DMD for Duchenne muscular dystrophy has received Rare Pediatric Disease Designation from the FDA, indicating potential for development in a high unmet need area.
Why It Matters
FDA's Rare Pediatric Disease Designation for PBGENE-DMD enhances Precision BioSciences' market potential, attracting investor interest due to potential future revenue from an underserved market.
Source: Business Wire
Market Sentiment:
Neutral
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
Precision BioSciences reported strong momentum in Q1 2025, focusing on clinical data generation for its in vivo gene editing therapies using its ARCUS® platform.
Why It Matters
Precision BioSciences' strong Q1 results and focus on clinical data may signal potential growth and advancements in gene editing, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences (DTIL) reported a Q3 loss of $2.21 per share, significantly worse than the expected loss of $0.43, compared to a loss of $0.35 per share a year earlier.
Why It Matters
Precision BioSciences' larger-than-expected quarterly loss signals potential operational issues, which may lead to decreased investor confidence and affect stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Precision BioSciences (Nasdaq: DTIL) is prioritizing its PBGENE-DMD program for Duchenne Muscular Dystrophy, showcasing its progress at a recent gene therapy conference.
Why It Matters
Precision BioSciences' acceleration of PBGENE-DMD signals potential breakthroughs in gene therapy, which could drive stock value and attract investor interest in innovative biotech solutions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its Q1 2025 financial results and business update on May 15, 2025. The company focuses on gene editing therapies using its ARCUS® platform.
Why It Matters
The announcement of Precision BioSciences' Q1 2025 financial results and business update date can influence investor sentiment, providing insights into performance and future growth potential in gene editing.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences (Nasdaq: DTIL) will present initial safety data from its Phase 1 ELIMINATE-B trial for PBGENE-HBV, targeting chronic hepatitis B, at the European Association for the Study of the Liver.
Why It Matters
Initial safety data from the Phase 1 trial could signal progress for Precision BioSciences' gene editing therapies, potentially influencing stock performance and market sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DTIL Stock
What is Precision Biosciences Inc.'s (DTIL) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Precision Biosciences Inc. (DTIL) has a median price target of $24.50. The highest price target is $60.00 and the lowest is $13.00.
Is DTIL stock a good investment in 2026?
According to current analyst ratings, DTIL has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DTIL stock?
Wall Street analysts predict DTIL stock could reach $24.50 in the next 12 months. This represents a 450.6% increase from the current price of $4.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precision Biosciences Inc.'s business model?
The company leverages its proprietary ARCUS genome editing platform to create therapeutic solutions for genetically-defined diseases, primarily generating revenue through the development of allogeneic CAR T cell therapies aimed at treating cancer. By focusing on precision editing and targeting specific diseases, it positions itself within the lucrative biopharmaceutical market.
What is the highest forecasted price for DTIL Precision Biosciences Inc.?
The highest price target for DTIL is $60.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,248.3% increase from the current price of $4.45.
What is the lowest forecasted price for DTIL Precision Biosciences Inc.?
The lowest price target for DTIL is $13.00 from at , which represents a 192.1% increase from the current price of $4.45.
What is the overall DTIL consensus from analysts for Precision Biosciences Inc.?
The overall analyst consensus for DTIL is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are DTIL stock price projections?
Stock price projections, including those for Precision Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 5:42 AM UTC